Ridaforolimus is an investigational oral mTOR inhibitor to treat metastatic soft-tissue or bone sarcomas in patients who responded to chemotherapy.
The European Medicines Agency had earlier accepted the marketing authorization application for ridaforolimus.
Merck is known for the development and worldwide commercialization of ridaforolimus in oncology.